Cannabis sativa L. preparations have been used in medicine for millenia. However, concern over the dangers of abuse led to the banning of the medicinal use of marijuana in most countries in the 1930s. Only recently, marijuana and individual natural and synthetic cannabinoid receptor agonists and antagonists, as well as chemically related compounds, whose mechanism of action is still obscure, have come back to being considered of therapeutic value.
A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety
As the legalization of medical cannabis continues across the USA, oncology care providers will be increasingly asked to provide recommendations regarding its use in the cancer setting. In this article, we review recent literature that analyzes cannabis use specifically in patients with cancer and provide an accessible guide for clinicians, researchers, and patients. Cannabis use appears well tolerated, with few serious adverse effects reported.
In the fall of 2018, University of Connecticut Professor Gerry Berkowitz taught a new, three-credit college course called “Horticulture of Cannabis: From Seed to Harvest,” and packed a 400-person lecture hall. The course was so popular that Berkowitz developed an online version, and in July 2019, 40 more students nationwide began watching him grow a hemp crop from seed.
Fall is the season to enjoy some delicious harvest. It’s also the time when you can enjoy the best cannabis strain from town. It’s the time to taste the best many top growers offer.
The onus of cannabinoids in interrupting the molecular odyssey of breast cancer: A critical perspective on UPRER and beyond
Cannabinoids, commonly used for medicinal and recreational purposes, consist of various complex hydrophobic molecules obtained from Cannabis sativa L. Acting as an inhibitory molecule; they have been investigated for their antineoplastic effect in various breast tumor models. The present study summarizes new achievements in understanding the extent of therapeutic progress and highlights recent developments in cannabinoid biology towards achieving a better cure of breast cancer through the exploitation of different cannabinoids.
The National Institute for Health and Care Excellence (Nice) announced today that it would not recommend cannabidiol combined with anti-seizure drug clobazam for the treatment of two types of severe epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
The I Try singer, 51, is planning on launching her own line of cannabis oil-based cosmetics and is a staunch advocate for the benefits of marijuana, claiming it has helped her mother ease the pain of cancer.
Cannabinoid receptors, endocannabinoids and the enzymes responsible for their biosynthesis and degradation constitute the endocannabinoid system. In recent decades, the endocannabinoid system has attracted considerable interest as a potential therapeutic target in numerous pathological conditions. Its involvement in several physiological processes is well known, such as in energy balance, appetite stimulation, blood pressure, pain modulation, embryogenesis, nausea and vomiting control, memory, learning and immune response, among others, as well as in pathological conditions where it exerts a protective role in the development of certain disorders.
What cancer patients actually know regarding medical cannabis? A cross-sectional survey with a critical analysis of the current attitudes
In Italy medical cannabis is a prescription drug since 1998. Even though it could not be considered a therapy as such, it is indicated as a symptomatic treatment also in cancer patients, to cure iatrogenic nausea/vomiting and chronic pain. Our survey shows that most of Italian cancer patients know medical cannabis and a third of them have considered using cannabis to treat one (or more) of their own health problems. In the same time, they are poorly informed and do not tend to ask for information about medical cannabis to healthcare professionals.
As we head into the heart of wildfire season (August-September), growers in California are on high alert after the disastrous wildfires of 2015, 2017, and 2018.